Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis
Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis
复制标题
CD56 对急性髓系白血病患者的预后价值：荟萃分析
DOI：
10.1007/s00432-015-1977-3
复制
发表时间：
2015-10-01
影响因子：
3.6
通讯作者：
Chen, Jieping
中科院分区：
文献类型：
--
作者：
Xu, Shuangnian;Li, Xi;Chen, Jieping
广泛的研究已经调查了CD56对急性髓系白血病(AML)患者的预后价值，但结果仍然不确定。通过对PubMed、Embase、Cochrane图书馆和CBM的系统搜索，找出了评估CD56在AML患者中的预后价值的研究。计算总生存率(OS)和无病生存率(DFS)的合并危险比(HR)和完全缓解率(CRR)和复发率(RR)的合并优势比(OR)，可信区间分别为95%和95%。在t(8；21)易位的AML中，CD56过表达与OS(HR 2.22；95%CI 1.30~3.78)和DFS(HR 2.63；95%CI 1.10~6.29)和RR增加(OR 3.29；95%CI 1.67~6.48)相关，但不影响CRR(OR 0.94；95%CI 0.49~1.80)。在t(15；17)易位的AML中，CD56过表达与OS缩短(HR 2.43；95%CI 1.66~3.57)和DFS(HR 4.27；95%CI 1.15~15.78)、RR增加(OR 3.11；95%CI 2.01~4.81)、CRR降低(OR 0.42；95%CI 0.25~0.72)相关。就AML整体而言，CD56过表达与OS(HR 1.74；95%CI 1.38~2.19)和DFS(HR 2.38；95%CI 1.87~3.02)、RR(OR 5.19；95%CI 2.84~9.48)和CRR降低(OR 0.62；95%CI 0.41~0.96)相关。
Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30-3.78) and DFS (HR 2.63; 95 % CI 1.10-6.29) and increased RR (OR 3.29; 95 % CI 1.67-6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49-1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66-3.57) and DFS (HR 4.27; 95 % CI 1.15-15.78), increased RR (OR 3.11; 95 % CI 2.01-4.81), and decreased CRR (OR 0.42; 95 % CI 0.25-0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38-2.19) and DFS (HR 2.38; 95 % CI 1.87-3.02), increased RR (OR 5.19; 95 % CI 2.84-9.48), and decreased CRR (OR 0.62; 95 % CI 0.41-0.96).This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.